2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Recruiting
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Other neoplasm
1
Gynecologic
1
CNS
1
Conditions
Neoplasms
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neuroblastoma
1
Neoplasms by Site
1
Lung Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
1282
Specimen Handling
927
Carboplatin
836
Magnetic Resonance Spectroscopy
834
Cyclophosphamide
807
Cisplatin
735
Nivolumab
680
Paclitaxel
635
Radiotherapy
617
Gemcitabine
580
Biopsy
559
Bevacizumab
485
Dexamethasone
444
fludarabine
410
Docetaxel
385
venetoclax
372
Oxaliplatin
367
Capecitabine
361
Fluorouracil
357
atezolizumab
350
durvalumab
340
Rituximab
335
Drug Therapy
333
Radiosurgery
321
Doxorubicin
319
Blood Specimen Collection
317
Standard of Care
311
Pemetrexed
307
Ipilimumab
303
Radiation
287
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Pregnancy Tests
×
1 year
×
Clear all
NCT06620835
2026-04-29
OPTALK
Groupe Francais De Pneumo-Cancerologie
Phase 2
Recruiting
45 enrolled
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled